AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04823598 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uncoached pushing and Hands-poised perineal protection
Description: Women will not be given any instructions regarding straining and breathing, and will be allowed to follow their own pushing impulses. During the expulsion of the fetal head, the hands of the researcher will be kept in the air and ready for the intervention, but pressure will not be applied to the fetal head or perineum unless necessary (fetal hypoxic appearance, strain detection with a risk of spontaneous laceration towards the anus in the midline).
Study NCT06534866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy
Description: 1. TENS+cold pack (For 10 mins on plantar ascpect of foot)~2. Stretching exercises (5 repetition 2 sets/day) Standing calf stretch Seated plantar fascia stretch Plantar fascia massage Achilles stretch Frozen can roll Towel stretch
Study NCT06534866 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy
Description: 1. TENS+cold pack (For 10 mins on plantar ascpect of foot)~2. Stretching exercises (5 repetition 2 sets/day) Standing calf stretch Seated plantar fascia stretch Plantar fascia massage Achilles stretch Frozen can roll Towel stretch
Study NCT06534866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: In the first step, after the metatarsophalangeal joints is dorsiflexed, the first strap will be adhered firmly to the posterior heel at its proximal end. The other end of the strap is cut into four slices of equal width. Each slice is applied with a 50% stretch (50% tensile strain) and attached to the plantar forefoot. In the second step, another strap is applied with gentle compression across the bases of the four slices beneath the foot and wrapped around the rearfoot
Study NCT04757649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention with Navigation Services
Description: A patient navigation (PN) intervention for SGM youth/emerging adults designed to target mechanisms (i.e., decreasing thwarted belongingness and increasing suicide-related coping skills) that theoretically underlie suicide. The proposed intervention will integrate a single-session, empirically supported, suicide prevention intervention (Safety Planning Intervention; SPI) with PN services (PN+SPI). The patient navigator will deliver the SPI and continue frequent contact for the purpose of providing motivational enhancement, problem-solving, reinforcing coping strategies, and connecting participants to social support and mental health resources (e.g., SGM-specific support groups within the community).
Study NCT05525624 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRAMPRE
Description: discharge interventions Transition Model is discharge interventions in parents of preterm infants.
Study NCT05525624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: routine neonatal clinic discharge training of the hospital
Study NCT05883306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]LXI-15028
Description: \[14C\]LXI-15028
Study NCT05307224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandala
Description: Experimental group will paint mandala for 30 minutes/day in the evenings for six consecutive days. Six pre-selected mandalas were planned to be printed separately on A4 paper. Each patient will be given a new mandala each day. Additionally, At the beginning of the study, the experimental group will be given six colors (yellow, blue, green, red, purple, brown).
Study NCT06475157 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention is applied.
Study NCT06342362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Participants would be randomly assigned to either the treatment group (receiving magnesium sulfate) or the control group (receiving a placebo or standard treatment).
Study NCT06342362 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo or standard treatment)
Description: placebo or standard treatment)
Study NCT06175728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S-Press
Description: Leg Strengthening Device that can be used in supine and seated positions
Study NCT04894474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 767551 intravenous
Description: BI 767551 intravenous
Study NCT04894474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 767551 inhalation
Description: BI 767551 inhalation
Study NCT04894474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo intravenous
Description: Placebo intravenous
Study NCT04894474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravenous
Description: Placebo intravenous
Study NCT04894474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhalation
Description: Placebo inhalation
Study NCT04894474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation
Description: Placebo inhalation
Study NCT05995912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib-tramadol
Description: Oral administration (with or without food)
Study NCT05995912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Oral administration (with or without food)
Study NCT05995912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Oral administration (with or without food)
Study NCT06338501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specifical Functional Training Exercises
Description: Strength Training: Include compound exercises like squats, deadlifts, lunges, and bench presses to build overall strength and muscle mass. Focus on functional movements that mimic the actions used in Muay Thai.~Core Stability Exercises: A strong core is essential for generating power and maintaining balance during strikes and defensive maneuvers.~Plyometric Training: Jumping exercises such as box jumps, squat jumps, and split jumps help improve explosive power and enhance muscular endurance, crucial for delivering swift and powerful strikes.~Flexibility and Mobility Training: Incorporate stretching exercises to improve flexibility, joint range of motion, and prevent injuries.~Interval Training: Perform high-intensity interval training (HIIT) sessions that combine cardiovascular exercises.
Study NCT06453668 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCD601
Description: Investigational Product
Study NCT05100056 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT06370169 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endoscopic ultrasound placement of Coil and glue
Description: The standard treatment of bleeding gastric varices is obliteration with placement of coil and glue
Study NCT06208917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron (Oral soluble film OR injections) ,Dexamethasone
Description: Participants will randomly assigned 1:1 to receive treatment (Oral soluble film of Ondansetron plus dexamethasone OR Ondansetron injections plus dexamethasone).
Study NCT06208917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron (Oral soluble film OR injections) ,Dexamethasone
Description: Participants will randomly assigned 1:1 to receive treatment (Oral soluble film of Ondansetron plus dexamethasone OR Ondansetron injections plus dexamethasone).
Study NCT05522192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone liposome
Description: Phase I: 24mg/m2, 30 mg/m2, 36mg/m2, IV, d1; Phase II: RP2D.
Study NCT05522192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Phase I/II: 100mg po d1，200mg po d2，400mg po d3-28.
Study NCT05065242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Sleep restriction, Stimulus control, sleep hygiene and cognitive techniques to handle sleep disturbing thoughts.
Study NCT04980638 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ER004
Description: Intra-amniotic route 100 mg/kg of estimated fetal weight per injection. 3 injections, approximately 3 weeks apart starting from gestational week 26
Study NCT05685485 — intervention group
Intervention type: PROCEDURE
Intervention: Standard Implantation
Description: Traditional Ahmed plantation without vicryl ligature
Study NCT05685485 — intervention group
Intervention type: PROCEDURE
Intervention: Tied off Tube
Description: Ahmed implantation with vicryl ligature
Study NCT04572633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HistoSonics System
Description: The HistoSonics System (System) is intended for the destruction of liver tissue using histotripsy, a non-thermal, mechanical process using focused ultrasound.
Study NCT06059703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood punction
Description: Peripheral blood sampling (5 ml) at inclusion and 3 months after treatment
Study NCT06059703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central blood sampling
Description: Central blood sampling (2 ml) at inclusion and 3 months after treatment
Study NCT06059703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracranial pressure measurement
Description: Intracranial pressure measurement at sinus level with micro-catheter at inclusion and 3 months after treatment
Study NCT05442411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: comparison of scalp block vs conventional post operative parecoxib
Study NCT04265079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional weight at hand
Description: Added weight of an inactive hand orthosis (300 gram)
Study NCT05406596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiquID GCE Use
Description: Use of the LiquID GCE to aid in percutaneous coronary intervention (PCI)
Study NCT05185024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate Capsules
Description: Once daily dose of one Ferrous Sulfate Capsule for 12 weeks in total.
Study NCT05185024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: >Your< Iron Forte Capsules
Description: Once daily dose of one >Your\< Iron Forte Capsule for 12 weeks in total.
Study NCT04772469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of multiple self-tests
Description: Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for men in their social networks.
Study NCT04772469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small monetary incentives
Description: Use of small incentive voucher (\~$5) to encourage linkage to confirmatory testing.
Study NCT05185024 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: >Your< Iron Forte Liquid
Description: Once daily dose of 5 ml of >Your\< Iron Forte Liquid for 12 weeks in total.
Study NCT05185024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blank Capsules
Description: Once daily dose of one Blank Capsule (excipients only) for 12 weeks in total.
Study NCT04772469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of SMS/text reminders to motivate adherence to ART or PrEP
Description: Messages will be motivational, will not include any identifying information and will include generic texts such as maintain your good health, to cater for status-neutral language that can work for both HIV positive individuals taking ARVs, as well as HIV-negative individuals on PrEP who may need adherence support.
Study NCT05001763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
Study NCT05185024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blank Liquid
Description: Once daily dose of 5 ml of Blank Liquid (excipients only) for 12 weeks in total.
Study NCT05001763 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose, 2mg, tablet.
Study NCT05128331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: spermidineLife
Description: dietary supplement that is made of natural wheat germ extract with high spermidine content
Study NCT05128331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dietary supplement that is made of cellulose.
Study NCT05832268 — intervention group
Intervention type: OTHER
Intervention: Obstetric Anal Sphincter Injury
Description: We will investigate if a new vaginal delivery in those with a previous obstetric anal sphincter injury affects the function of anal musculature negatively
Study NCT05274568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]UCB-2897
Description: Investigational Agent:~\[18F\]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product \[18F\]UCB2897is delivered in normal saline (0.9 % sodium chloride \[NaCl\]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. \[18F\]UCB2897 will be stored at ambient temperature in its original container.
Study NCT05381883 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Participants will answer socio-demographic questions, questions about the lifetime experience of potentially traumatic events, the presence of a known psychological or medical disorder and the taking of medication, and a series of psychological assessment questionnaires.~The questionnaires, performed outside routine care, are as follows :~Posttraumatic stress disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 Beck Depression Inventory-Fast Screen General Anxiety Disorder-7 Coping Inventory for Stressful Situations Maslach Burnout Inventory Medical Outcomes Study Short-Form~The total time for completing the questionnaires is estimated at 20 minutes
Study NCT05603169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity resistance Exercise Training
Description: The resistance training will consist of five resistance exercises (thrice a week on non-consecutive days): squat, leg press, knee extension, lunges, and abdominal crunches. Every participant will be assessed pre and post intervention for hormonal change, BMI/anthropometric measures, fasting glucose and quality of life.The plan will be followed for 12 weeks
Study NCT05603169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity aerobic Exercise Training
Description: The training protocol will begin with a 5-minute warm-up and will end with a 5-minute cool down, during which the HR will be 60-75% of the HRmax. At least 90 min of exercise per week for obese PCOS patients, with treadmill walking that may include whole-body movement involving more than 2/3 of the muscles, the exercise intensity will be high intensity
Study NCT05734313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified protocol for cognitive behavioral therapy (UP-CBT)
Description: UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.
Study NCT05734313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring (CGM)
Description: Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
Study NCT05734313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Description: Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
Study NCT06532006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX22
Description: HLX22 15mg/kg Q3w
Study NCT06532006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg q3w
Study NCT06532006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W
Study NCT06532006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W
Study NCT06532006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 ,Q3W
Study NCT06532006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 ,Q3W
Study NCT06532006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
Study NCT06532006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
Study NCT06141954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound waves therapy
Description: Therapeutic ultrasound is proposed to deliver energy to deep tissue sites through ultrasonic waves, to produce increases in tissue temperature or non- thermal physiologic changes. Low level laser therapy penetrates particularly light waves that increase cellular metabolism.
Study NCT04616651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Survey
Description: Participants respond to online survey questions either before or after using the Chatbot O2O intervention.
Study NCT04616651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Survey
Description: Participants respond to online survey questions either before or after using the Chatbot O2O intervention.
Study NCT04616651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot prototype
Description: An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).
Study NCT04616651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chatbot prototype
Description: An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).
Study NCT04616651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open to Options (O2O) Program
Description: Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.
Study NCT04616651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Open to Options (O2O) Program
Description: Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.